Drawing for ON-CHIP DRUG DISCOVERY

USPTO serial 99768436

ON-CHIP DRUG DISCOVERY

Reviewed by CopyMark Law Group

Status 641Office Action
Filing date
Status date
Registration date
—
Examiner
AURAND, KYLE C
Law office
TMO LAW OFFICE 126

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 641: Status 641 means the USPTO mailed a non-final Office Action identifying issues with your application. You typically have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.

Deadline: November 26, 2026

Need help with ON-CHIP DRUG DISCOVERY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Office Action issues

The examiner has refused registration due to a likelihood of confusion with existing trademarks and requires a disclaimer of the wording 'DRUG DISCOVERY'. This is a serious issue.

Owner

Goods and services

ClassDescriptionStatusFirst use
009Medical laboratory research instruments for evaluating pharmaceuticals, such as antibodies; Plates, glass slides or chips having multi-well arrays that can be used in chemical analysis, biological analysis or patterning for scientific, laboratory or medical research use; Sensor chips for scientific useACTIVE—
042Drug discovery services; Pharmaceutical products development; Pharmaceutical research services; Pharmaceutical product evaluation; Pharmaceutical drug development services; Pharmaceutical research and development; Development of pharmaceutical preparations and medicines; Technical research in the field of pharmaceutical studies; Research and development services of new pharmaceutical products; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of pharmaceutical preparations; Pharmaceutical research in the field of therapeutic discovery and development; Testing of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Research on the subject of pharmaceuticals; Laboratory research in the field of pharmaceuticals; Development of pharmaceuticals for cell and gene therapies; Testing of pharmaceuticals for cell and gene therapies; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Conducting early evaluations in the field of new pharmaceuticals; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Laboratory services for the production of pharmaceuticals in the nature of testing of pharmaceuticals, including antibody-based therapeutics; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development services in the field of antibodies; Medical research; Medical research services; Medical research laboratory services; Medical research in the field of oncology; Medical research in the field of infectious diseases; Medical research services in the field of cancer; Medical research in the field of rare diseases; Medical research laboratory services in the field of oncology; Research and development services in the field of medical preparations; Scientific research for medical purposes in the area of cancerous diseases; Providing information about medical research in the field of therapeutic discovery and development; Medical and scientific research in the field of cancer treatment and diagnosis; Technology research in the field of therapeutic discovery and development; Medical research in the field of therapeutic discovery and development; Research and development in the field of therapeutic discovery and development; Scientific research for medical purposes in the field of therapeutic discovery and development; Medical and scientific research in the field of therapeutic discovery and development; Medical and scientific research information in the field of therapeutic discovery and development; Laboratory services for biomanufacturing; Laboratory services for biomanufacturing of antibodies, peptides, and proteins for therapeutic evaluation; Biological research; Biological research and analysis; Biological research laboratory services; Biological research in the field of therapeutic discovery and development; Research in the field of synthetic biology; Biomedical research services; Biomedical research in the field of therapeutic discovery and development; Biotechnology research; Research and development in the field of biotechnology; Research and development services in the field of biotechnology; Biotechnology research in the field of therapeutic discovery and developmentACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (GNRN): A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.

DateCodeEventWhat it means
Aug 26, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 24, 2026DOCKASSIGNED TO EXAMINER—
Aug 20, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 16, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 16, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance